In a prophylactic study, mice receiving a modified vaccinia Ankara vaccine expressing human p53, MVA-p53, followed by an Lm-based vaccine expressing human p53, LmddA-LLO-p53, resulted in greater anti-tumor protection against the murine breast cancer model, 4T1p53 (124). This evidence concerns the gene TP53 and breast carcinoma.